Free Trial

Silicon Laboratories (SLAB) Financials

Silicon Laboratories logo
$125.38 +3.95 (+3.25%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$125.37 -0.01 (-0.01%)
As of 05/27/2025 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Silicon Laboratories

Annual Income Statements for Silicon Laboratories

This table shows Silicon Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/28/2024 12/30/2023 12/31/2022 1/1/2022 1/2/2021 12/28/2019 12/29/2018 12/30/2017 12/31/2016 1/2/2016
Net Income / (Loss) Attributable to Common Shareholders
-191 -35 91 2,117 13 19 84 47 61 30
Consolidated Net Income / (Loss)
-191 -35 91 2,117 13 19 84 47 61 30
Net Income / (Loss) Continuing Operations
-191 -35 91 -58 -115 -103 84 47 61 30
Total Pre-Tax Income
-155 -11 126 -58 -132 -96 72 77 64 30
Total Operating Income
-165 -24 119 -33 -107 -89 85 85 66 32
Total Gross Profit
312 461 643 425 295 280 521 454 422 381
Total Revenue
584 782 1,024 721 511 474 868 769 698 645
Operating Revenue
584 782 1,024 721 511 474 868 769 698 645
Total Cost of Revenue
272 322 382 295 216 194 347 315 276 264
Operating Cost of Revenue
272 322 382 295 216 194 347 315 276 264
Total Operating Expenses
478 485 523 458 402 369 436 369 355 349
Selling, General & Admin Expense
145 147 191 185 167 163 198 160 155 160
Research & Development Expense
332 338 332 273 235 206 238 209 200 188
Total Other Income / (Expense), net
11 14 7.19 -25 -25 -7.37 -13 -8.07 -1.78 -1.97
Interest Expense
1.31 5.55 6.72 31 34 20 20 14 2.59 2.83
Interest & Investment Income
12 19 14 5.70 9.03 13 6.65 6.06 0.81 0.86
Income Tax Expense
36 7.94 38 13 -15 6.98 -11 30 3.00 0.68
Other Gains / (Losses), net
0.00 -16 3.40 14 2.12 0.32 - - - -
Basic Earnings per Share
($5.93) ($1.09) $2.61 $49.44 $0.29 $0.44 $1.94 $1.11 $1.47 $0.70
Weighted Average Basic Shares Outstanding
32.19M 31.80M 35.09M 42.83M 43.78M 43.35M 43.16M 42.45M 41.71M 42.31M
Diluted Earnings per Share
($5.93) ($1.09) $2.54 $47.78 $0.28 $0.43 $1.90 $1.09 $1.45 $0.69
Weighted Average Diluted Shares Outstanding
32.19M 31.80M 36.04M 44.32M 44.37M 44.29M 44.04M 43.33M 42.38M 42.95M
Weighted Average Basic & Diluted Shares Outstanding
32.46M 31.90M 31.90M 38.20M 43.93M 43.50M 557.30M 42.40M 41.80M 42.30M

Quarterly Income Statements for Silicon Laboratories

This table shows Silicon Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/28/2024 9/28/2024 6/29/2024 3/30/2024 12/30/2023 9/30/2023 7/1/2023 4/1/2023 12/31/2022 10/1/2022
Net Income / (Loss) Attributable to Common Shareholders
-24 -29 -82 -57 -70 10 11 14 25 21
Consolidated Net Income / (Loss)
-24 -29 -82 -57 -70 10 11 14 25 21
Net Income / (Loss) Continuing Operations
-24 -29 -82 -57 -70 10 11 14 25 21
Total Pre-Tax Income
-26 -26 -45 -57 -70 14 23 23 27 33
Total Operating Income
-29 -30 -48 -59 -73 12 17 20 24 30
Total Gross Profit
90 90 77 55 44 119 144 154 157 166
Total Revenue
166 166 145 106 87 204 245 247 257 270
Operating Revenue
166 166 145 106 87 204 245 247 257 270
Total Cost of Revenue
76 76 69 51 43 85 101 93 100 104
Operating Cost of Revenue
76 76 69 51 43 85 101 93 100 104
Total Operating Expenses
119 120 125 114 117 107 127 134 133 135
Selling, General & Admin Expense
36 37 39 34 34 28 41 45 47 51
Research & Development Expense
82 83 86 81 83 79 86 89 87 85
Total Other Income / (Expense), net
2.72 3.21 2.53 2.22 2.67 1.58 6.18 3.18 2.45 3.15
Interest Expense
0.26 0.28 0.26 0.51 0.94 1.36 1.60 1.66 1.85 1.53
Interest & Investment Income
2.98 3.49 2.79 2.73 3.61 2.94 7.78 4.84 4.30 4.67
Income Tax Expense
-2.09 2.01 37 -0.39 -16 3.39 12 7.75 1.58 14
Basic Earnings per Share
($0.72) ($0.88) ($2.56) ($1.77) ($2.21) $0.33 $0.35 $0.44 $0.77 $0.62
Weighted Average Basic Shares Outstanding
32.19M 32.31M 32.12M 31.91M 31.80M 31.80M 31.61M 31.96M 35.09M 34.08M
Diluted Earnings per Share
($0.72) ($0.88) ($2.56) ($1.77) ($2.15) $0.32 $0.33 $0.41 $0.76 $0.60
Weighted Average Diluted Shares Outstanding
32.19M 32.31M 32.12M 31.91M 31.80M 32.08M 32.93M 33.75M 36.04M 34.78M
Weighted Average Basic & Diluted Shares Outstanding
32.46M 32.45M 32.29M 31.92M 31.90M 31.78M 31.86M 32.00M 31.90M 33.28M

Annual Cash Flow Statements for Silicon Laboratories

This table details how cash moves in and out of Silicon Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/28/2024 12/30/2023 12/31/2022 1/1/2022 1/2/2021 12/28/2019 12/29/2018 12/30/2017 12/31/2016 1/2/2016
Net Change in Cash & Equivalents
54 -272 -575 872 -24 30 -72 128 27 -28
Net Cash From Operating Activities
-14 -30 141 91 -8.84 22 174 190 129 105
Net Cash From Continuing Operating Activities
-14 -30 141 91 -8.84 22 174 190 129 105
Net Income / (Loss) Continuing Operations
-191 -35 91 -58 -115 -103 84 47 61 30
Consolidated Net Income / (Loss)
-191 -35 91 2,117 13 19 84 47 61 30
Depreciation Expense
26 26 23 18 16 15 16 15 13 13
Amortization Expense
23 26 36 67 64 51 57 37 28 29
Non-Cash Adjustments To Reconcile Net Income
62 64 57 46 51 44 50 45 38 41
Changes in Operating Assets and Liabilities, net
67 -112 -66 17 -25 14 -33 46 -11 -6.55
Net Cash From Investing Activities
113 470 241 -477 -358 -103 -197 -374 -50 -49
Net Cash From Continuing Investing Activities
113 470 241 -477 -358 -103 -197 -374 -50 -49
Purchase of Property, Plant & Equipment
-12 -23 -27 -30 -19 -23 -36 -17 -20 -18
Purchase of Investments
-74 -103 -607 -1,542 -520 -425 -396 -636 -185 -107
Divestitures
12 0.00 0.00 - - - - - - -
Sale and/or Maturity of Investments
186 596 874 1,095 497 345 474 294 162 172
Net Cash From Financing Activities
-45 -712 -887 -1,299 201 -30 -49 313 -52 -84
Net Cash From Continuing Financing Activities
-45 -712 -887 -1,299 201 -30 -49 313 -52 -84
Repayment of Debt
-45 -571 -0.02 -141 -625 -1.13 0.00 -83 -5.00 -95
Repurchase of Common Equity
-0.02 -217 -883 -1,150 -16 -27 -39 0.00 -41 -71
Issuance of Debt
0.00 80 0.00 0.00 845 0.00 0.00 400 0.00 81
Issuance of Common Equity
16 15 12 14 15 14 13 12 13 17
Other Financing Activities, net
-16 -18 -15 -22 -18 -16 -23 -16 -20 -16
Other Net Changes in Cash
0.00 0.00 -69 2,556 142 140 - - - -
Cash Interest Paid
0.99 4.47 4.43 5.01 8.66 6.37 6.23 3.86 2.22 2.47
Cash Income Taxes Paid
19 32 132 266 7.22 10 21 8.93 11 2.16

Quarterly Cash Flow Statements for Silicon Laboratories

This table details how cash moves in and out of Silicon Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/28/2024 9/28/2024 6/29/2024 3/30/2024 12/30/2023 9/30/2023 7/1/2023 4/1/2023 12/31/2022 10/1/2022
Net Change in Cash & Equivalents
-21 62 49 -36 68 -75 -482 216 17 -22
Net Cash From Operating Activities
10 32 16 -72 19 -33 -2.22 -13 14 44
Net Cash From Continuing Operating Activities
10 32 16 -72 19 -33 -2.22 -13 14 44
Net Income / (Loss) Continuing Operations
-24 -29 -82 -57 -70 10 11 14 25 21
Consolidated Net Income / (Loss)
-24 -29 -82 -57 -70 10 11 14 25 21
Depreciation Expense
6.25 6.15 6.52 6.63 6.72 6.55 6.21 6.24 6.01 5.95
Amortization Expense
5.44 5.44 6.08 6.08 6.21 6.26 6.83 7.03 7.25 8.63
Non-Cash Adjustments To Reconcile Net Income
16 16 16 14 26 5.85 15 18 17 14
Changes in Operating Assets and Liabilities, net
6.12 33 70 -42 49 -62 -41 -58 -42 -5.67
Net Cash From Investing Activities
-38 30 40 81 43 10 162 254 200 69
Net Cash From Continuing Investing Activities
-38 30 40 81 43 10 162 254 200 69
Purchase of Property, Plant & Equipment
-3.96 -2.21 -3.53 -2.05 -3.87 -5.25 -6.02 -7.66 -6.47 -7.74
Purchase of Investments
-45 -11 -7.91 -9.79 -12 -10 -15 -66 -28 -25
Sale and/or Maturity of Investments
11 43 51 81 59 26 183 328 234 102
Net Cash From Financing Activities
6.58 0.42 -6.40 -46 5.65 -52 -641 -25 -197 -103
Net Cash From Continuing Financing Activities
6.58 0.42 -6.40 -46 5.65 -52 -641 -25 -197 -103
Repurchase of Common Equity
-0.02 - - 0.00 - -16 -183 -18 -202 -103
Issuance of Common Equity
6.95 1.29 7.77 0.34 6.60 0.23 7.79 0.00 5.41 0.00
Other Financing Activities, net
-0.36 -0.87 -14 -1.05 -0.95 -0.93 -9.38 -6.93 -0.66 -0.77

Annual Balance Sheets for Silicon Laboratories

This table presents Silicon Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/28/2024 12/30/2023 12/31/2022 1/1/2022 1/2/2021 12/28/2019 12/29/2018 12/30/2017 12/31/2016 1/2/2016
Total Assets
1,223 1,443 2,169 2,958 1,993 1,675 1,624 1,535 1,082 1,011
Total Current Assets
602 738 1,461 2,239 976 944 827 948 491 423
Cash & Equivalents
282 228 500 1,075 203 227 197 269 141 114
Short-Term Investments
101 212 692 965 522 499 417 495 154 129
Accounts Receivable
54 29 71 98 95 76 73 71 74 74
Inventories, net
106 194 100 49 48 73 75 73 60 54
Prepaid Expenses
60 75 98 52 87 69 65 39 62 53
Plant, Property, & Equipment, net
132 146 152 147 136 136 139 128 130 131
Total Noncurrent Assets
489 559 556 573 882 595 659 460 461 457
Long-Term Investments
76 123 95 78 77 - - - - 7.13
Goodwill
376 376 376 376 376 398 397 288 276 273
Intangible Assets
36 60 85 119 163 134 171 83 104 121
Total Liabilities & Shareholders' Equity
1,223 1,443 2,169 2,958 1,993 1,675 1,624 1,535 1,082 1,011
Total Liabilities
143 234 764 746 794 560 557 582 255 250
Total Current Liabilities
98 164 186 669 284 138 145 162 140 142
Short-Term Debt
0.00 45 0.00 451 134 0.00 - - - 10
Accounts Payable
42 57 90 47 55 39 41 39 40 42
Current Deferred Revenue
3.07 2.12 6.78 14 13 19 22 50 46 35
Other Current Liabilities
52 59 89 157 82 80 81 73 55 -
Total Noncurrent Liabilities
45 71 579 77 509 422 412 420 115 108
Other Noncurrent Operating Liabilities
45 71 49 77 80 - - - - -
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,080 1,209 1,405 2,212 1,200 1,115 1,067 953 827 761
Total Preferred & Common Equity
1,080 1,209 1,405 2,212 1,200 1,115 1,067 953 827 761
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,080 1,209 1,405 2,212 1,200 1,115 1,067 953 827 761
Common Stock
78 17 0.00 0.00 204 134 108 103 24 14
Retained Earnings
1,002 1,193 1,416 2,215 994 981 961 851 802 748
Accumulated Other Comprehensive Income / (Loss)
0.07 -1.03 -11 -2.42 1.81 0.65 -1.57 -1.16 0.49 -0.51

Quarterly Balance Sheets for Silicon Laboratories

This table presents Silicon Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/28/2024 6/29/2024 3/30/2024 9/30/2023 7/1/2023 4/1/2023 10/1/2022
Total Assets
1,249 1,250 1,344 1,475 1,519 2,161 2,336
Total Current Assets
614 600 646 774 821 1,461 1,626
Cash & Equivalents
303 241 191 160 235 716 483
Short-Term Investments
67 98 141 257 271 436 893
Accounts Receivable
49 41 33 102 98 88 77
Inventories, net
139 166 198 168 146 133 88
Prepaid Expenses
56 54 83 87 71 88 84
Plant, Property, & Equipment, net
135 139 142 151 152 152 152
Total Noncurrent Assets
500 511 556 551 545 549 559
Long-Term Investments
81 87 126 109 97 94 91
Goodwill
376 376 376 376 376 376 376
Intangible Assets
42 47 53 66 72 78 92
Total Liabilities & Shareholders' Equity
1,249 1,250 1,344 1,475 1,519 2,161 2,336
Total Liabilities
168 157 179 215 260 742 785
Total Current Liabilities
118 100 111 165 219 693 206
Short-Term Debt
0.00 0.00 0.00 45 80 530 0.00
Accounts Payable
45 39 45 48 55 71 82
Current Deferred Revenue
8.48 3.32 3.92 10 11 11 12
Other Current Liabilities
65 57 63 62 72 81 112
Total Noncurrent Liabilities
50 57 67 50 41 49 579
Other Noncurrent Operating Liabilities
50 57 67 50 41 49 50
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,081 1,093 1,166 1,260 1,259 1,419 1,552
Total Preferred & Common Equity
1,081 1,093 1,166 1,260 1,259 1,419 1,552
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,081 1,093 1,166 1,260 1,259 1,419 1,552
Common Stock
56 39 30 0.00 0.00 0.00 0.00
Retained Earnings
1,026 1,054 1,136 1,263 1,263 1,426 1,568
Accumulated Other Comprehensive Income / (Loss)
0.27 -0.25 -0.48 -2.60 -4.09 -6.46 -16

Annual Metrics And Ratios for Silicon Laboratories

This table displays calculated financial ratios and metrics derived from Silicon Laboratories' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/28/2024 12/30/2023 12/31/2022 1/1/2022 1/2/2021 12/28/2019 12/29/2018 12/30/2017 12/31/2016 1/2/2016
Growth Metrics
- - - - - - - - - -
Revenue Growth
-25.30% -23.62% 42.07% 41.09% 7.84% -45.43% 12.93% 10.21% 8.19% 3.89%
EBITDA Growth
-519.21% -84.32% 238.87% 295.70% -20.64% -114.06% 15.30% 27.91% 45.11% -9.54%
EBIT Growth
-585.15% -120.25% 463.18% 69.34% -20.81% -204.03% 0.28% 28.21% 105.61% -37.03%
NOPAT Growth
-585.15% -120.37% 461.07% 69.34% -20.81% -162.86% 89.69% -17.66% 100.53% -20.95%
Net Income Growth
-453.40% -137.76% -95.68% 16,797.29% -34.95% -76.95% 77.51% -23.42% 107.85% -22.19%
EPS Growth
-444.04% -142.91% -94.68% 16,964.29% -34.88% -77.37% 74.31% -24.83% 110.14% -20.69%
Operating Cash Flow Growth
54.17% -121.48% 54.91% 1,131.77% -139.86% -87.22% -8.43% 47.02% 22.25% -23.28%
Free Cash Flow Firm Growth
21.98% -218.11% -117.59% 79.93% 891.99% 95.23% -275.09% 100.23% 188.71% -152.61%
Invested Capital Growth
-9.97% 6.68% 18.67% -19.29% -16.61% -6.30% 42.21% -5.93% 2.87% 15.07%
Revenue Q/Q Growth
15.72% -17.89% 4.99% 28.46% 60.86% -43.17% 1.70% 2.45% 3.34% -0.29%
EBITDA Q/Q Growth
27.00% -77.76% 8.25% 1,250.99% 76.02% -116.76% -2.09% 8.14% 15.24% -4.28%
EBIT Q/Q Growth
21.19% -133.07% 21.91% 63.97% 41.65% -243.37% -8.61% 8.02% 29.98% -15.89%
NOPAT Q/Q Growth
21.19% -132.60% 37.55% 63.97% 41.65% -307.78% 37.43% -32.80% 28.89% -12.66%
Net Income Q/Q Growth
19.40% -156.93% 45.21% -0.57% -5.77% -21.99% 31.44% -34.64% 30.72% -12.86%
EPS Q/Q Growth
19.43% -159.89% 22.71% 0.19% -9.68% -21.82% 31.94% -34.73% 29.46% -12.66%
Operating Cash Flow Q/Q Growth
-152.82% 13.36% -17.08% 380.77% 90.42% -86.42% -10.21% 15.80% 3.42% -10.08%
Free Cash Flow Firm Q/Q Growth
-2,382.90% 47.29% 89.87% -83.21% 115.38% -110.10% 16.59% 7.58% -13.41% -50.44%
Invested Capital Q/Q Growth
-1.27% -11.31% 5.64% 49.10% -36.79% 0.12% 1.25% 2.57% 7.84% 4.29%
Profitability Metrics
- - - - - - - - - -
Gross Margin
53.42% 58.88% 62.74% 59.01% 57.71% 59.14% 60.05% 59.07% 60.42% 59.05%
EBITDA Margin
-20.00% 3.56% 17.37% 7.28% -5.25% -4.69% 18.21% 17.84% 15.37% 11.46%
Operating Margin
-28.32% -3.09% 11.65% -4.56% -20.96% -18.71% 9.81% 11.05% 9.50% 5.00%
EBIT Margin
-28.32% -3.09% 11.65% -4.56% -20.96% -18.71% 9.81% 11.05% 9.50% 5.00%
Profit (Net Income) Margin
-32.69% -4.41% 8.93% 293.73% 2.45% 4.07% 9.63% 6.12% 8.81% 4.59%
Tax Burden Percent
123.38% 327.38% 72.28% -3,639.71% -9.48% -20.07% 115.84% 61.24% 95.35% 97.76%
Interest Burden Percent
93.55% 43.65% 106.03% 177.16% 123.45% 108.31% 84.69% 90.50% 97.31% 93.89%
Effective Tax Rate
0.00% 0.00% 30.41% 0.00% 0.00% 0.00% -15.84% 38.76% 4.65% 2.24%
Return on Invested Capital (ROIC)
-17.64% -2.53% 13.90% -3.76% -10.08% -7.40% 13.39% 8.29% 9.90% 5.36%
ROIC Less NNEP Spread (ROIC-NNEP)
-2.23% 0.24% 13.21% -199.25% -31.23% -39.57% 18.93% 10.17% 10.99% 6.48%
Return on Net Nonoperating Assets (RNNOA)
0.95% -0.12% -8.85% 127.87% 11.16% 9.17% -5.11% -3.00% -2.16% -1.47%
Return on Equity (ROE)
-16.69% -2.64% 5.05% 124.11% 1.08% 1.77% 8.28% 5.29% 7.74% 3.90%
Cash Return on Invested Capital (CROIC)
-7.15% -8.99% -3.17% 17.59% 8.03% -0.90% -21.47% 14.39% 7.07% -8.66%
Operating Return on Assets (OROA)
-12.42% -1.34% 4.65% -1.33% -5.84% -5.37% 5.39% 6.49% 6.33% 3.14%
Return on Assets (ROA)
-14.33% -1.91% 3.57% 85.52% 0.68% 1.17% 5.29% 3.60% 5.88% 2.88%
Return on Common Equity (ROCE)
-16.69% -2.64% 5.05% 124.11% 1.08% 1.77% 8.28% 5.29% 7.74% 3.90%
Return on Equity Simple (ROE_SIMPLE)
-17.69% -2.86% 6.51% 95.70% 1.04% 1.73% 7.83% 4.94% 7.44% 3.89%
Net Operating Profit after Tax (NOPAT)
-116 -17 83 -23 -75 -62 99 52 63 32
NOPAT Margin
-19.82% -2.16% 8.10% -3.19% -14.67% -13.10% 11.37% 6.77% 9.06% 4.89%
Net Nonoperating Expense Percent (NNEP)
-15.41% -2.76% 0.69% 195.49% 21.15% 32.17% -5.54% -1.89% -1.09% -1.12%
Return On Investment Capital (ROIC_SIMPLE)
-10.73% -1.35% 4.29% - - - - - - -
Cost of Revenue to Revenue
46.58% 41.12% 37.26% 40.99% 42.29% 40.86% 39.95% 40.93% 39.58% 40.95%
SG&A Expenses to Revenue
24.89% 18.79% 18.65% 25.67% 32.64% 34.44% 22.79% 20.77% 22.29% 24.89%
R&D to Revenue
56.85% 43.18% 32.45% 37.90% 46.03% 43.41% 27.45% 27.25% 28.63% 29.16%
Operating Expenses to Revenue
81.74% 61.97% 51.10% 63.57% 78.67% 77.85% 50.24% 48.02% 50.92% 54.05%
Earnings before Interest and Taxes (EBIT)
-165 -24 119 -33 -107 -89 85 85 66 32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-117 28 178 52 -27 -22 158 137 107 74
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
3.84 3.48 3.21 3.75 4.65 4.53 3.17 3.94 3.28 2.65
Price to Tangible Book Value (P/TBV)
6.22 5.44 4.78 4.83 8.46 8.68 6.79 6.46 6.07 5.50
Price to Revenue (P/Rev)
7.10 5.37 4.41 11.51 10.92 10.67 3.90 4.89 3.89 3.13
Price to Earnings (P/E)
0.00 0.00 49.40 3.92 445.37 262.33 40.52 79.81 44.13 68.21
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 2.02% 25.52% 0.22% 0.38% 2.47% 1.25% 2.27% 1.47%
Enterprise Value to Invested Capital (EV/IC)
5.93 5.33 5.80 12.14 7.90 5.86 3.68 5.61 3.92 3.00
Enterprise Value to Revenue (EV/Rev)
6.31 4.71 3.67 9.20 10.46 10.03 3.67 4.44 3.63 2.92
Enterprise Value to EBITDA (EV/EBITDA)
0.00 132.17 21.13 126.30 0.00 0.00 20.15 24.90 23.63 25.53
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 31.51 0.00 0.00 0.00 37.39 40.18 38.23 58.51
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 45.28 0.00 0.00 0.00 32.27 65.61 40.10 59.85
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 26.60 72.69 0.00 214.19 18.36 18.02 19.66 17.89
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 61.66 89.43 0.00 0.00 37.78 56.13 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.04 0.38 0.20 0.47 0.38 0.39 0.44 0.14 0.16
Long-Term Debt to Equity
0.00 0.00 0.38 0.00 0.36 0.38 0.39 0.44 0.14 0.14
Financial Leverage
-0.43 -0.49 -0.67 -0.64 -0.36 -0.23 -0.27 -0.29 -0.20 -0.23
Leverage Ratio
1.16 1.38 1.42 1.45 1.58 1.51 1.56 1.47 1.32 1.35
Compound Leverage Factor
1.09 0.60 1.50 2.57 1.96 1.64 1.32 1.33 1.28 1.27
Debt to Total Capital
0.00% 3.59% 27.37% 16.92% 31.95% 27.46% 27.86% 30.58% 12.23% 13.43%
Short-Term Debt to Total Capital
0.00% 3.59% 0.00% 16.92% 7.63% 0.00% 0.00% 0.00% 0.00% 1.14%
Long-Term Debt to Total Capital
0.00% 0.00% 27.37% 0.00% 24.33% 27.46% 27.86% 30.58% 12.23% 12.29%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 96.41% 72.63% 83.08% 68.05% 72.54% 72.14% 69.42% 87.77% 86.57%
Debt to EBITDA
0.00 1.61 2.98 8.59 -21.01 -18.99 2.61 3.06 1.07 1.60
Net Debt to EBITDA
0.00 -18.56 -4.26 -31.75 8.87 13.67 -1.28 -2.51 -1.68 -1.79
Long-Term Debt to EBITDA
0.00 0.00 2.98 0.00 -15.99 -18.99 2.61 3.06 1.07 1.46
Debt to NOPAT
0.00 -2.66 6.38 -19.60 -7.52 -6.80 4.18 8.07 1.82 3.75
Net Debt to NOPAT
0.00 30.61 -9.12 72.50 3.17 4.90 -2.04 -6.62 -2.85 -4.19
Long-Term Debt to NOPAT
0.00 0.00 6.38 0.00 -5.72 -6.80 4.18 8.07 1.82 3.43
Altman Z-Score
19.11 12.88 5.82 8.57 5.41 6.92 5.69 5.95 8.66 6.95
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
6.15 4.51 7.87 3.35 3.43 6.85 5.71 5.84 3.51 2.97
Quick Ratio
4.46 2.86 6.80 3.20 2.88 5.82 4.74 5.15 2.64 2.22
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-47 -60 -19 108 60 -7.54 -158 90 45 -51
Operating Cash Flow to CapEx
-118.40% -133.09% 532.61% 306.70% -45.80% 95.48% 488.51% 1,101.10% 653.44% 596.86%
Free Cash Flow to Firm to Interest Expense
-35.83 -10.83 -2.81 3.46 1.75 -0.37 -8.04 6.40 17.45 -17.99
Operating Cash Flow to Interest Expense
-10.62 -5.46 21.01 2.94 -0.26 1.10 8.81 13.41 49.83 37.29
Operating Cash Flow Less CapEx to Interest Expense
-19.59 -9.57 17.07 1.98 -0.82 -0.05 7.01 12.20 42.20 31.04
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.44 0.43 0.40 0.29 0.28 0.29 0.55 0.59 0.67 0.63
Accounts Receivable Turnover
13.95 15.53 12.07 7.45 5.98 6.37 12.01 10.55 9.43 8.96
Inventory Turnover
1.82 2.18 5.10 6.08 3.57 2.62 4.68 4.74 4.87 4.96
Fixed Asset Turnover
4.20 5.25 6.86 5.11 3.76 3.45 6.51 5.98 5.35 4.89
Accounts Payable Turnover
5.45 4.37 5.56 5.78 4.61 4.84 8.67 8.02 6.76 6.52
Days Sales Outstanding (DSO)
26.16 23.50 30.25 48.98 61.01 57.33 30.39 34.60 38.72 40.75
Days Inventory Outstanding (DIO)
201.10 167.20 71.62 60.02 102.13 139.56 77.92 76.97 75.00 73.62
Days Payable Outstanding (DPO)
67.01 83.60 65.62 63.17 79.26 75.49 42.10 45.49 54.00 56.02
Cash Conversion Cycle (CCC)
160.25 107.10 36.25 45.83 83.87 121.40 66.21 66.08 59.71 58.35
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
622 691 648 546 676 811 866 609 647 629
Invested Capital Turnover
0.89 1.17 1.72 1.18 0.69 0.57 1.18 1.22 1.09 1.10
Increase / (Decrease) in Invested Capital
-69 43 102 -130 -135 -55 257 -38 18 82
Enterprise Value (EV)
3,688 3,686 3,758 6,629 5,343 4,750 3,186 3,414 2,534 1,886
Market Capitalization
4,146 4,203 4,515 8,295 5,581 5,054 3,387 3,759 2,714 2,018
Book Value per Share
$33.28 $38.03 $42.21 $55.05 $27.38 $25.71 $24.74 $22.39 $19.81 $18.31
Tangible Book Value per Share
$20.56 $24.32 $28.35 $42.73 $15.06 $13.43 $11.57 $13.66 $10.71 $8.83
Total Capital
1,080 1,254 1,935 2,663 1,763 1,537 1,480 1,373 942 879
Total Debt
0.00 45 530 451 563 422 412 420 115 118
Total Long-Term Debt
0.00 0.00 530 0.00 429 422 412 420 115 108
Net Debt
-458 -518 -757 -1,666 -238 -304 -202 -344 -180 -132
Capital Expenditures (CapEx)
12 23 27 30 19 23 36 17 20 18
Debt-free, Cash-free Net Working Capital (DFCFNWC)
122 180 84 -19 101 80 68 21 56 48
Debt-free Net Working Capital (DFNWC)
504 619 1,276 2,020 826 806 682 785 351 291
Net Working Capital (NWC)
504 574 1,276 1,570 691 806 682 785 351 281
Net Nonoperating Expense (NNE)
75 18 -8.41 -2,140 -87 -81 15 4.94 1.70 1.93
Net Nonoperating Obligations (NNO)
-458 -518 -757 -1,666 -523 -304 -202 -344 -180 -132
Total Depreciation and Amortization (D&A)
49 52 59 85 80 66 73 52 41 42
Debt-free, Cash-free Net Working Capital to Revenue
20.87% 23.03% 8.17% -2.62% 19.79% 16.92% 7.83% 2.77% 8.04% 7.42%
Debt-free Net Working Capital to Revenue
86.27% 79.18% 124.56% 280.27% 161.63% 170.15% 78.52% 102.14% 50.34% 45.10%
Net Working Capital to Revenue
86.27% 73.42% 124.56% 217.76% 135.31% 170.15% 78.52% 102.14% 50.34% 43.55%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($5.93) ($1.09) $2.61 $49.44 $0.29 $0.44 $1.94 $1.11 $1.47 $0.70
Adjusted Weighted Average Basic Shares Outstanding
32.19M 31.80M 35.09M 42.83M 43.78M 43.35M 43.16M 42.45M 41.71M 42.31M
Adjusted Diluted Earnings per Share
($5.93) ($1.09) $2.54 $47.78 $0.28 $0.43 $1.90 $1.09 $1.45 $0.69
Adjusted Weighted Average Diluted Shares Outstanding
32.19M 31.80M 36.04M 44.32M 44.37M 44.29M 44.04M 43.33M 42.38M 42.95M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
32.46M 31.90M 31.90M 38.20M 43.93M 43.50M 43.09M 42.71M 41.89M 41.55M
Normalized Net Operating Profit after Tax (NOPAT)
-116 -17 83 -23 -75 -62 60 52 63 32
Normalized NOPAT Margin
-19.82% -2.16% 8.10% -3.19% -14.67% -13.10% 6.87% 6.77% 9.06% 4.89%
Pre Tax Income Margin
-26.49% -1.35% 12.35% -8.07% -25.88% -20.26% 8.31% 10.00% 9.25% 4.69%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-126.33 -4.35 17.74 -1.06 -3.14 -4.38 4.33 6.01 25.62 11.40
NOPAT to Interest Expense
-88.43 -3.04 12.35 -0.74 -2.20 -3.07 5.01 3.68 24.43 11.14
EBIT Less CapEx to Interest Expense
-135.30 -8.45 13.79 -2.02 -3.70 -5.53 2.52 4.80 17.99 5.15
NOPAT Less CapEx to Interest Expense
-97.40 -7.15 8.40 -1.70 -2.76 -4.21 3.21 2.46 16.80 4.90
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.01% -629.09% 966.53% 54.31% 129.97% 138.68% 46.99% 0.00% 65.93% 241.49%

Quarterly Metrics And Ratios for Silicon Laboratories

This table displays calculated financial ratios and metrics derived from Silicon Laboratories' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/28/2024 9/28/2024 6/29/2024 3/30/2024 12/30/2023 9/30/2023 7/1/2023 4/1/2023 12/31/2022 10/1/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
91.43% -18.34% -40.63% -56.90% -66.25% -24.48% -6.95% 5.55% 23.31% 45.98%
EBITDA Growth
71.85% -172.41% -217.28% -241.35% -261.18% -44.15% -34.52% -33.77% 56.97% 273.68%
EBIT Growth
60.84% -343.17% -379.73% -402.12% -403.68% -59.58% -45.29% -41.72% 812.28% 425.85%
NOPAT Growth
60.84% -325.63% -515.18% -420.79% -326.03% -46.95% -61.40% -40.89% 1,125.67% 367.57%
Net Income Growth
65.86% -375.45% -849.88% -504.71% -375.17% -50.72% -50.50% -39.03% 918.62% -98.99%
EPS Growth
66.51% -375.00% -875.76% -531.71% -382.89% -46.67% -45.00% -29.31% 162.07% -98.72%
Operating Cash Flow Growth
-45.36% 194.73% 826.76% -440.66% 33.76% -175.80% -20.98% -115.59% -67.74% 3.62%
Free Cash Flow Firm Growth
151.74% 181.80% 122.68% 74.70% -19.13% 31.75% -177.01% -126.93% -159.90% -132.94%
Invested Capital Growth
-9.97% -19.13% -9.36% 0.45% 6.68% 27.07% 28.57% 36.74% 18.67% 67.48%
Revenue Q/Q Growth
-0.09% 14.47% 36.66% 22.49% -57.38% -16.79% -0.78% -4.10% -4.63% 2.53%
EBITDA Q/Q Growth
6.52% 48.84% 23.69% 22.87% -340.49% -17.14% -8.03% -12.05% -16.67% -2.86%
EBIT Q/Q Growth
3.64% 38.14% 18.79% 19.12% -698.44% -28.83% -12.29% -18.70% -20.34% -3.68%
NOPAT Q/Q Growth
3.64% 38.14% 18.79% 19.12% -655.27% 13.84% -37.25% -43.01% 30.33% -17.17%
Net Income Q/Q Growth
16.42% 65.31% -45.34% 19.00% -774.40% -5.55% -21.56% -44.93% 20.77% -5.13%
EPS Q/Q Growth
18.18% 65.63% -44.63% 17.67% -771.88% -3.03% -19.51% -46.05% 26.67% 0.00%
Operating Cash Flow Q/Q Growth
-67.97% 96.03% 122.47% -487.33% 155.52% -1,403.83% 83.28% -195.83% -68.53% 2,500.11%
Free Cash Flow Firm Q/Q Growth
-61.90% 263.74% 179.11% 52.81% 39.77% -0.85% 11.75% -122.21% 65.49% -213.80%
Invested Capital Q/Q Growth
-1.27% -5.52% -5.62% 2.27% -11.31% 5.89% 4.59% 8.61% 5.64% 7.14%
Profitability Metrics
- - - - - - - - - -
Gross Margin
54.27% 54.28% 52.68% 51.77% 50.58% 58.41% 58.72% 62.35% 61.13% 61.37%
EBITDA Margin
-10.19% -10.89% -24.37% -43.64% -69.30% 12.28% 12.33% 13.31% 14.51% 16.61%
Operating Margin
-17.22% -17.85% -33.03% -55.59% -84.19% 6.00% 7.01% 7.93% 9.36% 11.20%
EBIT Margin
-17.22% -17.85% -33.03% -55.59% -84.19% 6.00% 7.01% 7.93% 9.36% 11.20%
Profit (Net Income) Margin
-14.33% -17.13% -56.52% -53.14% -80.36% 5.08% 4.47% 5.66% 9.86% 7.78%
Tax Burden Percent
91.95% 107.57% 180.59% 99.32% 99.07% 75.01% 46.92% 61.39% 95.61% 62.93%
Interest Burden Percent
90.51% 89.20% 94.74% 96.24% 96.35% 112.92% 136.02% 116.25% 110.18% 110.41%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 24.56% 52.84% 34.07% 5.95% 42.52%
Return on Invested Capital (ROIC)
-10.73% -8.96% -17.88% -35.41% -68.85% 6.19% 5.15% 8.90% 15.10% 12.82%
ROIC Less NNEP Spread (ROIC-NNEP)
-9.95% -7.30% -7.65% -32.84% -65.93% 6.03% 4.78% 8.81% 14.87% 12.60%
Return on Net Nonoperating Assets (RNNOA)
4.24% 2.91% 3.08% 14.92% 32.15% -3.04% -2.60% -5.68% -9.96% -9.66%
Return on Equity (ROE)
-6.49% -6.05% -14.79% -20.49% -36.70% 3.15% 2.55% 3.23% 5.13% 3.16%
Cash Return on Invested Capital (CROIC)
-7.15% 0.29% -6.95% -10.66% -8.99% -16.39% -15.79% -18.91% -3.17% -38.13%
Operating Return on Assets (OROA)
-7.55% -6.62% -12.94% -20.36% -36.46% 3.00% 3.63% 3.29% 3.74% 3.66%
Return on Assets (ROA)
-6.28% -6.35% -22.14% -19.46% -34.80% 2.54% 2.32% 2.35% 3.94% 2.54%
Return on Common Equity (ROCE)
-6.49% -6.05% -14.79% -20.49% -36.70% 3.15% 2.55% 3.23% 5.13% 3.16%
Return on Equity Simple (ROE_SIMPLE)
0.00% -21.91% -18.13% -9.01% 0.00% 4.81% 5.66% 5.81% 0.00% 4.06%
Net Operating Profit after Tax (NOPAT)
-20 -21 -34 -41 -51 9.22 8.10 13 23 17
NOPAT Margin
-12.05% -12.50% -23.12% -38.91% -58.93% 4.52% 3.31% 5.23% 8.80% 6.44%
Net Nonoperating Expense Percent (NNEP)
-0.78% -1.65% -10.23% -2.58% -2.92% 0.16% 0.37% 0.10% 0.22% 0.23%
Return On Investment Capital (ROIC_SIMPLE)
-1.86% - - - -4.08% - - - 1.17% -
Cost of Revenue to Revenue
45.73% 45.72% 47.32% 48.23% 49.42% 41.59% 41.28% 37.65% 38.87% 38.63%
SG&A Expenses to Revenue
21.90% 22.11% 26.62% 31.54% 38.73% 13.63% 16.62% 18.19% 18.10% 18.80%
R&D to Revenue
49.59% 50.02% 59.10% 75.82% 96.04% 38.79% 35.08% 36.22% 33.67% 31.36%
Operating Expenses to Revenue
71.49% 72.13% 85.72% 107.36% 134.77% 52.42% 51.71% 54.41% 51.77% 50.17%
Earnings before Interest and Taxes (EBIT)
-29 -30 -48 -59 -73 12 17 20 24 30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-17 -18 -35 -46 -60 25 30 33 37 45
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
3.84 3.48 3.23 3.92 3.48 2.93 4.01 3.93 3.21 2.72
Price to Tangible Book Value (P/TBV)
6.22 5.67 5.28 6.21 5.44 4.52 6.23 5.79 4.78 3.90
Price to Revenue (P/Rev)
7.10 7.45 6.51 7.12 5.37 3.88 4.95 5.39 4.41 4.33
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 60.90 70.81 67.73 49.40 67.12
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 1.64% 1.41% 1.48% 2.02% 1.49%
Enterprise Value to Invested Capital (EV/IC)
5.93 5.25 4.66 5.81 5.33 4.12 6.15 6.92 5.80 5.36
Enterprise Value to Revenue (EV/Rev)
6.31 6.56 5.73 6.40 4.71 3.37 4.44 4.70 3.67 3.37
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 132.17 25.61 31.16 30.22 21.13 20.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 43.98 49.70 46.27 31.51 33.59
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 61.94 75.10 65.91 45.28 54.46
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 106.70 113.81 26.60 19.29
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 1,610.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.04 0.04 0.06 0.37 0.38 0.34
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.38 0.34
Financial Leverage
-0.43 -0.40 -0.40 -0.45 -0.49 -0.50 -0.54 -0.64 -0.67 -0.77
Leverage Ratio
1.16 1.16 1.18 1.36 1.38 1.36 1.38 1.46 1.42 1.42
Compound Leverage Factor
1.05 1.04 1.12 1.31 1.33 1.53 1.87 1.70 1.56 1.57
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 3.59% 3.45% 5.98% 27.19% 27.37% 25.43%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 3.59% 3.45% 5.98% 27.19% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 27.37% 25.43%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 96.41% 96.55% 94.02% 72.81% 72.63% 74.57%
Debt to EBITDA
0.00 0.00 0.00 0.00 1.61 0.36 0.55 3.29 2.98 3.22
Net Debt to EBITDA
0.00 0.00 0.00 0.00 -18.56 -3.83 -3.60 -4.44 -4.26 -5.71
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.98 3.22
Debt to NOPAT
0.00 0.00 0.00 0.00 -2.66 0.87 1.33 7.18 6.38 8.77
Net Debt to NOPAT
0.00 0.00 0.00 0.00 30.61 -9.27 -8.68 -9.69 -9.12 -15.55
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.38 8.77
Altman Z-Score
19.48 15.40 15.47 17.34 12.77 12.67 14.00 6.38 5.67 5.36
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
6.15 5.19 5.99 5.80 4.51 4.68 3.76 2.11 7.87 7.90
Quick Ratio
4.46 3.54 3.80 3.28 2.86 3.14 2.76 1.79 6.80 7.06
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
49 128 35 -45 -94 -157 -155 -176 -79 -230
Operating Cash Flow to CapEx
255.59% 1,432.38% 457.05% -3,507.57% 478.50% -635.78% -36.88% -173.44% 214.25% 569.39%
Free Cash Flow to Firm to Interest Expense
187.94 461.30 134.05 -87.56 -100.14 -115.36 -97.40 -106.37 -42.87 -150.44
Operating Cash Flow to Interest Expense
38.96 113.77 61.35 -141.06 19.66 -24.57 -1.39 -8.02 7.49 28.84
Operating Cash Flow Less CapEx to Interest Expense
23.72 105.82 47.92 -145.08 15.55 -28.43 -5.16 -12.64 4.00 23.78
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.44 0.37 0.39 0.37 0.43 0.50 0.52 0.41 0.40 0.33
Accounts Receivable Turnover
13.95 6.69 7.78 10.67 15.53 10.66 11.96 12.43 12.07 13.07
Inventory Turnover
1.82 1.56 1.59 1.69 2.18 2.96 3.63 4.20 5.10 4.91
Fixed Asset Turnover
4.20 3.53 3.72 4.36 5.25 6.30 6.75 6.91 6.86 6.61
Accounts Payable Turnover
5.45 5.16 5.25 4.83 4.37 5.84 5.29 5.84 5.56 5.19
Days Sales Outstanding (DSO)
26.16 54.58 46.93 34.21 23.50 34.25 30.52 29.38 30.25 27.93
Days Inventory Outstanding (DIO)
201.10 234.39 229.54 215.99 167.20 123.36 100.60 86.89 71.62 74.32
Days Payable Outstanding (DPO)
67.01 70.78 69.54 75.60 83.60 62.52 68.95 62.53 65.62 70.33
Cash Conversion Cycle (CCC)
160.25 218.18 206.93 174.60 107.10 95.09 62.17 53.74 36.25 31.91
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
622 630 667 707 691 779 736 704 648 613
Invested Capital Turnover
0.89 0.72 0.77 0.91 1.17 1.37 1.56 1.70 1.72 1.99
Increase / (Decrease) in Invested Capital
-69 -149 -69 3.17 43 166 164 189 102 247
Enterprise Value (EV)
3,688 3,312 3,106 4,109 3,686 3,212 4,524 4,869 3,758 3,286
Market Capitalization
4,146 3,763 3,532 4,567 4,203 3,693 5,047 5,585 4,515 4,225
Book Value per Share
$33.28 $33.49 $34.24 $36.53 $38.03 $39.54 $39.34 $44.50 $42.21 $45.34
Tangible Book Value per Share
$20.56 $20.54 $20.96 $23.06 $24.32 $25.66 $25.33 $30.24 $28.35 $31.66
Total Capital
1,080 1,081 1,093 1,166 1,254 1,305 1,339 1,950 1,935 2,081
Total Debt
0.00 0.00 0.00 0.00 45 45 80 530 530 529
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 530 529
Net Debt
-458 -451 -426 -459 -518 -481 -523 -716 -757 -938
Capital Expenditures (CapEx)
3.96 2.21 3.53 2.05 3.87 5.25 6.02 7.66 6.47 7.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)
122 126 161 202 180 236 177 145 84 44
Debt-free Net Working Capital (DFNWC)
504 496 500 535 619 653 682 1,298 1,276 1,420
Net Working Capital (NWC)
504 496 500 535 574 608 602 767 1,276 1,420
Net Nonoperating Expense (NNE)
3.78 7.71 49 15 19 -1.13 -2.86 -1.06 -2.72 -3.63
Net Nonoperating Obligations (NNO)
-458 -451 -426 -459 -518 -481 -523 -716 -757 -938
Total Depreciation and Amortization (D&A)
12 12 13 13 13 13 13 13 13 15
Debt-free, Cash-free Net Working Capital to Revenue
20.87% 24.98% 29.64% 31.48% 23.03% 24.80% 17.33% 14.02% 8.17% 4.46%
Debt-free Net Working Capital to Revenue
86.27% 98.19% 92.18% 83.32% 79.18% 68.58% 66.98% 125.11% 124.56% 145.57%
Net Working Capital to Revenue
86.27% 98.19% 92.18% 83.32% 73.42% 63.86% 59.13% 74.00% 124.56% 145.57%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.72) ($0.88) ($2.56) ($1.77) ($2.21) $0.33 $0.35 $0.44 $0.77 $0.62
Adjusted Weighted Average Basic Shares Outstanding
32.19M 32.31M 32.12M 31.91M 31.80M 31.80M 31.61M 31.96M 35.09M 34.08M
Adjusted Diluted Earnings per Share
($0.72) ($0.88) ($2.56) ($1.77) ($2.15) $0.32 $0.33 $0.41 $0.76 $0.60
Adjusted Weighted Average Diluted Shares Outstanding
32.19M 32.31M 32.12M 31.91M 31.80M 32.08M 32.93M 33.75M 36.04M 34.78M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
32.46M 32.45M 32.29M 31.92M 31.90M 31.78M 31.86M 32.00M 31.90M 33.28M
Normalized Net Operating Profit after Tax (NOPAT)
-20 -21 -34 -41 -51 9.22 12 13 23 17
Normalized NOPAT Margin
-12.05% -12.50% -23.12% -38.91% -58.93% 4.52% 4.91% 5.23% 8.80% 6.44%
Pre Tax Income Margin
-15.58% -15.93% -31.30% -53.50% -81.11% 6.77% 9.54% 9.22% 10.31% 12.37%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-110.10 -106.86 -182.59 -116.18 -77.53 8.99 10.76 11.82 13.02 19.79
NOPAT to Interest Expense
-77.07 -74.80 -127.81 -81.32 -54.27 6.78 5.07 7.79 12.25 11.38
EBIT Less CapEx to Interest Expense
-125.35 -114.81 -196.01 -120.20 -81.64 5.13 6.98 7.20 9.52 14.73
NOPAT Less CapEx to Interest Expense
-92.32 -82.75 -141.23 -85.35 -58.38 2.92 1.30 3.17 8.75 6.31
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.01% 0.00% -8.10% -190.01% -629.09% 690.83% 709.12% 901.33% 966.53% 1,816.51%

Frequently Asked Questions About Silicon Laboratories' Financials

When does Silicon Laboratories's financial year end?

According to the most recent income statement we have on file, Silicon Laboratories' fiscal year ends in December. Their fiscal year 2024 ended on December 28, 2024.

How has Silicon Laboratories' net income changed over the last 9 years?

Silicon Laboratories' net income appears to be on an upward trend, with a most recent value of -$191.01 million in 2024, falling from $29.59 million in 2015. The previous period was -$34.52 million in 2023. Find out what analysts predict for Silicon Laboratories in the coming months.

What is Silicon Laboratories's operating income?
Silicon Laboratories's total operating income in 2024 was -$165.49 million, based on the following breakdown:
  • Total Gross Profit: $312.19 million
  • Total Operating Expenses: $477.68 million
How has Silicon Laboratories revenue changed over the last 9 years?

Over the last 9 years, Silicon Laboratories' total revenue changed from $644.83 million in 2015 to $584.39 million in 2024, a change of -9.4%.

How much debt does Silicon Laboratories have?

Silicon Laboratories' total liabilities were at $142.65 million at the end of 2024, a 39.1% decrease from 2023, and a 43.0% decrease since 2015.

How much cash does Silicon Laboratories have?

In the past 9 years, Silicon Laboratories' cash and equivalents has ranged from $114.09 million in 2015 to $1.07 billion in 2021, and is currently $281.61 million as of their latest financial filing in 2024.

How has Silicon Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, Silicon Laboratories' book value per share changed from 18.31 in 2015 to 33.28 in 2024, a change of 81.8%.



This page (NASDAQ:SLAB) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners